Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer
Savolitinib, a small-molecule inhibitor of the receptor tyrosine kinase mesenchymal-epithelial transition (MET) factor, was approved for the treatment of non-small cell lung cancer (NSCLC) by the China National Medical Products Administration in June 2021. Its safety for NSCLC treatment has been con...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1089184/full |
| _version_ | 1797935130958888960 |
|---|---|
| author | Ye Xiong Qing Cao Yongzheng Guo Xiang Liu Xueling Zhu Bohao Dai Biao Zhu |
| author_facet | Ye Xiong Qing Cao Yongzheng Guo Xiang Liu Xueling Zhu Bohao Dai Biao Zhu |
| author_sort | Ye Xiong |
| collection | DOAJ |
| description | Savolitinib, a small-molecule inhibitor of the receptor tyrosine kinase mesenchymal-epithelial transition (MET) factor, was approved for the treatment of non-small cell lung cancer (NSCLC) by the China National Medical Products Administration in June 2021. Its safety for NSCLC treatment has been confirmed in several prospective cohort studies. Herein, we report a rare case of shock, a serious adverse event, after treatment with savolitinib in an HIV-1–positive patient with advanced NSCLC. A 38-year-old man with an 8-year history of HIV-1 positivity was diagnosed with NSCLC 5 years ago; the lung cancer recurred after surgical resection. Despite chemotherapy, immunotherapy, and targeted therapy, tumor progression continued. He received savolitinib because of MET amplification. In the first 2 weeks of savolitinib use, he developed a mild rash on his trunk. In the following month, he was hospitalized for fever and circulatory shock thrice after taking savolitinib 400 mg. He had no urticaria or eosinophilia. During the three hospitalizations, he was negative for pathogens. His condition gradually improved after treatment with antibiotics, steroids, and vasopressors. Attention should be paid to the occurrence of septic shock-like presentations when using savolitinib in HIV-1 patients with NSCLC. |
| first_indexed | 2024-04-10T18:10:39Z |
| format | Article |
| id | doaj.art-a2f19e366f6d4374b1c91dc9a8020419 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T18:10:39Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-a2f19e366f6d4374b1c91dc9a80204192023-02-02T11:18:17ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-02-011410.3389/fphar.2023.10891841089184Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancerYe XiongQing CaoYongzheng GuoXiang LiuXueling ZhuBohao DaiBiao ZhuSavolitinib, a small-molecule inhibitor of the receptor tyrosine kinase mesenchymal-epithelial transition (MET) factor, was approved for the treatment of non-small cell lung cancer (NSCLC) by the China National Medical Products Administration in June 2021. Its safety for NSCLC treatment has been confirmed in several prospective cohort studies. Herein, we report a rare case of shock, a serious adverse event, after treatment with savolitinib in an HIV-1–positive patient with advanced NSCLC. A 38-year-old man with an 8-year history of HIV-1 positivity was diagnosed with NSCLC 5 years ago; the lung cancer recurred after surgical resection. Despite chemotherapy, immunotherapy, and targeted therapy, tumor progression continued. He received savolitinib because of MET amplification. In the first 2 weeks of savolitinib use, he developed a mild rash on his trunk. In the following month, he was hospitalized for fever and circulatory shock thrice after taking savolitinib 400 mg. He had no urticaria or eosinophilia. During the three hospitalizations, he was negative for pathogens. His condition gradually improved after treatment with antibiotics, steroids, and vasopressors. Attention should be paid to the occurrence of septic shock-like presentations when using savolitinib in HIV-1 patients with NSCLC.https://www.frontiersin.org/articles/10.3389/fphar.2023.1089184/fullshockadverse drug rectiontargeted therapysavolitinibHIV-1 |
| spellingShingle | Ye Xiong Qing Cao Yongzheng Guo Xiang Liu Xueling Zhu Bohao Dai Biao Zhu Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer Frontiers in Pharmacology shock adverse drug rection targeted therapy savolitinib HIV-1 |
| title | Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer |
| title_full | Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer |
| title_fullStr | Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer |
| title_full_unstemmed | Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer |
| title_short | Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer |
| title_sort | case report savolitinib induced severe adverse reactions resembling septic shock in an hiv 1 positive patient with advanced non small cell lung cancer |
| topic | shock adverse drug rection targeted therapy savolitinib HIV-1 |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1089184/full |
| work_keys_str_mv | AT yexiong casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer AT qingcao casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer AT yongzhengguo casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer AT xiangliu casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer AT xuelingzhu casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer AT bohaodai casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer AT biaozhu casereportsavolitinibinducedsevereadversereactionsresemblingsepticshockinanhiv1positivepatientwithadvancednonsmallcelllungcancer |